Amgen goes to FDA early with new leukemia drug

Amgen ($AMGN), which recently said it would cut back its R&D operations by closing a center in Seattle, is hoping to redeem its drug development rep by going to the FDA with an application for its new leukemia drug blinatumomab based on promising Phase II data, FierceBiotech reports. New immuno-oncology therapies that spur an immune system attack on cancer have become the rage. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.